Agenus INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

16 Mar 2026

AGEN

10-K: Agenus Strengthens Liquidity, Advances Lead Cancer Therapy

Agenus Inc. reports significantly reduced net losses and improved cash flow in 2025, bolstered by a strategic manufacturing facility sale and promising clinical data for its lead immunotherapy.

NASDAQ

17 Mar 2025

AGEN

Agenus INC

10-K: Agenus Inc. Reports 2024 Results, Prioritizes Botensilimab Development

Agenus Inc. outlines its 2024 financial results and strategic realignment, focusing on the development and commercialization of its botensilimab/balstilimab program.

NASDAQ

14 Mar 2024

AGEN

Agenus INC

10-K: Agenus Inc. 2023 Annual Report: Focus on Immuno-Oncology and Strategic Partnerships

Agenus Inc.'s 2023 annual report highlights its focus on immuno-oncology, strategic partnerships, and the advancement of its lead drug candidates.